• Net profit was up 2.7% YoY at Rs 596.5 cr. • Revenue was up 32% YoY at Rs 3,762.2 cr.
•Biocon Biologics’ new Multi-Product, Monoclonal Antibodies (mAbs) Facility received EU GMP certification for bBevacizumab.
• Consolidated net profit fell 32.29% YoY at Rs 1,665.95 cr. • The numbers fell because of much higher tax outgo for the quarter. • Revenue was up 18.36% YoY at Rs 18,662.38 cr. • Board of the company has recommended a dividend of Rs 38/share.
Swipe Up
Check More Details